However, in breast and ovarian cancer cells with BRCA1 deficiency, 53BP1 signaling in the S/G2 phases is no longer inhibited, and RIF1 and PTIP translocate to DNA break sites via binding to phosphorylated 53BP1 to protect DNA ends from processing. This evidence concerns the gene PAXIP1 and ovarian cancer.